Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016, Article ID 4780872, 9 pages
http://dx.doi.org/10.1155/2016/4780872
Review Article

TAMH: A Useful In Vitro Model for Assessing Hepatotoxic Mechanisms

Pacific University School of Pharmacy, 222 SE 8th Avenue No. 451, Hillsboro, OR 97123, USA

Received 22 September 2016; Revised 10 November 2016; Accepted 24 November 2016

Academic Editor: Hemant Kumar

Copyright © 2016 Madison Davis and Brendan D. Stamper. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Wu, G. Merlino, K. Cveklova, B. Mosinger Jr., and N. Fausto, “Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1,” Cancer Research, vol. 54, no. 22, pp. 5964–5973, 1994. View at Google Scholar · View at Scopus
  2. N. Fausto, “Growth factors in liver development, regeneration and carcinogenesis,” Progress in Growth Factor Research, vol. 3, no. 3, pp. 219–234, 1991. View at Publisher · View at Google Scholar · View at Scopus
  3. J. T. Brooling, J. S. Campbell, C. Mitchell, G. C. Yeoh, and N. Fausto, “Differential regulation of rodent hepatocyte and oval cell proliferation by interferon γ,” Hepatology, vol. 41, no. 4, pp. 906–915, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. L. D. DeLeve and N. Kaplowitz, “Glutathione metabolism and its role in hepatotoxicity,” Pharmacology and Therapeutics, vol. 52, no. 3, pp. 287–305, 1991. View at Publisher · View at Google Scholar · View at Scopus
  5. O. W. Griffith and R. T. Mulcahy, “The enzymes of glutathione synthesis: γ-glutamylcysteine synthetase,” Advances in Enzymology and Related Areas of Molecular Biology, vol. 73, pp. 209–267, 1999. View at Google Scholar · View at Scopus
  6. C. C. Franklin, M. E. Rosenfeld-Franklin, C. White, T. J. Kavanagh, and N. Fausto, “TGFbeta1-induced suppression of glutathione antioxidant defenses in hepatocytes: caspase-dependent post-translational and caspase-independent transcriptional regulatory mechanisms,” The FASEB Journal, vol. 17, no. 11, pp. 1535–1537, 2003. View at Google Scholar · View at Scopus
  7. L. Braun, J. E. Mead, M. Panzica, R. Mikumo, G. I. Bell, and N. Fausto, “Transforming growth factor β mRNA increases during liver regeneration: a possible paracrine mechanism of growth regulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 85, no. 5, pp. 1539–1543, 1988. View at Publisher · View at Google Scholar · View at Scopus
  8. R. H. Pierce, J. S. Campbell, A. B. Stephenson et al., “Disruption of redox homeostasis in tumor necrosis factor-induced apoptosis in a murine hepatocyte cell line,” American Journal of Pathology, vol. 157, no. 1, pp. 221–236, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. C. M. Knudson and S. J. Korsmeyer, “Bcl-2 and bax function independently to regulate cell death,” Nature Genetics, vol. 16, no. 4, pp. 358–363, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. H. Jaeschke and M. L. Bajt, “Intracellular signaling mechanisms of acetaminophen-induced liver cell death,” Toxicological Sciences, vol. 89, no. 1, pp. 31–41, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Hamid Boulares, A. J. Zoltoski, B. A. Stoica, O. Cuvillier, and M. E. Smulson, “Acetaminophen induces a caspase-dependent and Bcl-xL sensitive apoptosis in human hepatoma cells and lymphocytes,” Pharmacology and Toxicology, vol. 90, no. 1, pp. 38–50, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. H. K. Ho, Z.-H. Hu, S.-P. Tzung et al., “BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death,” Biochemical Pharmacology, vol. 69, no. 1, pp. 147–157, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. P. S. Schwartz, M. K. Manion, C. B. Emerson et al., “2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition,” Molecular Cancer Therapeutics, vol. 6, no. 7, pp. 2073–2080, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Jaeschke, M. R. McGill, and A. Ramachandran, “Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity,” Drug Metabolism Reviews, vol. 44, no. 1, pp. 88–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. T. W. Kensler, N. Wakabayashi, and S. Biswal, “Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway,” Annual Review of Pharmacology and Toxicology, vol. 47, pp. 89–116, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Sun, Z. Huang, and D. D. Zhang, “Phosphorylation of Nrf2 at multiple sites by MAP kinases has a limited contribution in modulating the Nrf2-dependent antioxidant response,” PLoS ONE, vol. 4, no. 8, Article ID e6588, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Itoh, K. I. Tong, and M. Yamamoto, “Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles,” Free Radical Biology and Medicine, vol. 36, no. 10, pp. 1208–1213, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. G. L. Johnson, H. G. Dohlman, and L. M. Graves, “MAPK kinase kinases (MKKKs) as a target class for small-molecule inhibition to modulate signaling networks and gene expression,” Current Opinion in Chemical Biology, vol. 9, no. 3, pp. 325–331, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. A. G. Turjanski, J. P. Vaqué, and J. S. Gutkind, “MAP kinases and the control of nuclear events,” Oncogene, vol. 26, no. 22, pp. 3240–3253, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. I. H. McKillop, C. M. Schmidt, P. A. Cahill, and J. V. Sitzmann, “Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma,” Hepatology, vol. 26, no. 6, pp. 1484–1491, 1997. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Osada, M. Kanematsu, H. Imai, S. Goshima, and Y. Sugiyama, “Evaluation of extracellular signal regulated kinase expression and its relation to treatment of hepatocellular carcinoma,” Journal of the American College of Surgeons, vol. 201, no. 3, pp. 405–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. C. M. Schmidt, I. H. McKillop, P. A. Cahill, and J. V. Sitzmann, “Increased MAPK expression and activity in primary human hepatocellular carcinoma,” Biochemical and Biophysical Research Communications, vol. 236, no. 1, pp. 54–58, 1997. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Tsuboi, T. Ichida, S. Sugitani et al., “Overexpression of extracellular signal-regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma,” Liver International, vol. 24, no. 5, pp. 432–436, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. G. H. Thoresen, T. K. Guren, D. Sandnes, M. Peak, L. Agius, and T. Christoffersen, “Response to transforming growth factor alpha (TGFalpha) and epidermal growth factor (EGF) in hepatocytes: lower EGF receptor affinity of TGFalpha is associated with more sustained activation of p42/p44 mitogen-activated protein kinase and greater efficacy in stimulation of DNA synthesis,” Journal of Cellular Physiology, vol. 175, no. 1, pp. 10–18, 1998. View at Google Scholar
  25. B. L. Bennett, D. T. Sasaki, B. W. Murray et al., “SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 24, pp. 13681–13686, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Latchoumycandane, C. W. Goh, M. M. K. Ong, and U. A. Boelsterli, “Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury,” Hepatology, vol. 45, no. 2, pp. 412–421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. W. M. Lee, “Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure,” Hepatology, vol. 40, no. 1, pp. 6–9, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Nourjah, S. R. Ahmad, C. Karwoski, and M. Willy, “Estimates of acetaminophen (paracetomal)-associated overdoses in the United States,” Pharmacoepidemiology and Drug Safety, vol. 15, no. 6, pp. 398–405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. J. A. Hinson, D. W. Roberts, and L. P. James, “Mechanisms of acetaminophen-induced liver necrosis,” in Handbook of Experimental Pharmacology, vol. 196, pp. 369–405, 2010. View at Google Scholar
  30. S. D. Nelson, M. A. Tirmenstein, M. S. Rashed, and T. G. Myers, “Acetaminophen and protein thiol modification,” in Biological Reactive Intermediates IV, vol. 283 of Advances in Experimental Medicine and Biology, pp. 579–588, Springer, New York, NY, USA, 1991. View at Google Scholar
  31. R. H. Pierce, C. C. Franklin, J. S. Campbell et al., “Cell culture model for acetaminophen-induced hepatocyte death in vivo,” Biochemical Pharmacology, vol. 64, no. 3, pp. 413–424, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Chen, L. L. Koenigs, S. J. Thompson et al., “Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6,” Chemical Research in Toxicology, vol. 11, no. 4, pp. 295–301, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. E. B. Nelson, “The pharmacology and toxicology of meta-substituted acetanilide I: acute toxicity of 3-hydroxyacetanilide in mice,” Research Communications in Chemical Pathology and Pharmacology, vol. 28, no. 3, pp. 447–456, 1980. View at Google Scholar · View at Scopus
  34. T. G. Myers, E. C. Dietz, N. L. Anderson, E. A. Khairallah, S. D. Cohen, and S. D. Nelson, “A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3′-hydroxyacetanilide,” Chemical Research in Toxicology, vol. 8, no. 3, pp. 403–413, 1995. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Qiu, L. Z. Benet, and A. L. Burlingame, “Identification of hepatic protein targets of the reactive metabolites of the non-hepatotoxic regioisomer of acetaminophen, 3′-hydroxyacetanilide, in the mouse in vivo using two-dimensional gel electrophoresis and mass spectrometry,” Advances in Experimental Medicine and Biology, vol. 500, pp. 663–673, 2001. View at Publisher · View at Google Scholar
  36. W. F. Salminen Jr., S. M. Roberts, N. R. Pumford, and J. A. Hinson, “Immunochemical comparison of 3′-hydroxyacetanilide and acetaminophen binding in mouse liver,” Drug Metabolism and Disposition, vol. 26, no. 3, pp. 267–271, 1998. View at Google Scholar · View at Scopus
  37. M. A. Tirmenstein and S. D. Nelson, “Subcellular binding and effects on calcium homeostasis produced by acetaminophen and a nonhepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver,” Journal of Biological Chemistry, vol. 264, no. 17, pp. 9814–9819, 1989. View at Google Scholar · View at Scopus
  38. Y. Xie, M. R. McGill, K. Du et al., “Mitochondrial protein adducts formation and mitochondrial dysfunction during N-acetyl-m-aminophenol (AMAP)-induced hepatotoxicity in primary human hepatocytes,” Toxicology and Applied Pharmacology, vol. 289, no. 2, pp. 213–222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  39. B. D. Stamper, I. Mohar, T. J. Kavanagh, and S. D. Nelson, “Proteomic analysis of acetaminophen-induced changes in mitochondrial protein expression using spectral counting,” Chemical Research in Toxicology, vol. 24, no. 4, pp. 549–558, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. B. D. Stamper, T. K. Bammler, R. P. Beyer, F. M. Farin, and S. D. Nelson, “Differential regulation of mitogen-activated protein kinase pathways by acetaminophen and its nonhepatotoxic regioisomer 3′-hydroxyacetanilide in TAMH cells,” Toxicological Sciences, vol. 116, no. 1, pp. 164–173, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Kon, J.-S. Kim, A. Uchiyama, H. Jaeschke, and J. J. Lemasters, “Lysosomal iron mobilization and induction of the mitochondrial permeability transition in acetaminophen-induced toxicity to mouse hepatocytes,” Toxicological Sciences, vol. 117, no. 1, pp. 101–108, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. R. R. Ramsay, M. S. Rashed, and S. D. Nelson, “In vitro effects of acetaminophen metabolites and analogs on the respiration of mouse liver mitochondria,” Archives of Biochemistry and Biophysics, vol. 273, no. 2, pp. 449–457, 1989. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Hai, C. D. Wolfgang, D. K. Marsee, A. E. Allen, and U. Sivaprasad, “ATF3 and stress responses,” Gene Expression, vol. 7, no. 4–6, pp. 321–335, 1999. View at Google Scholar · View at Scopus
  44. B. D. Stamper, M. L. Garcia, D. Q. Nguyen et al., “P53 contributes to differentiating gene expression following exposure to acetaminophen and its less hepatotoxic regioisomer both in vitro and in vivo,” Gene Regulation and Systems Biology, vol. 9, pp. 1–14, 2015. View at Publisher · View at Google Scholar · View at Scopus
  45. A. V. Vaseva and U. M. Moll, “The mitochondrial p53 pathway,” Biochimica et Biophysica Acta (BBA)—Bioenergetics, vol. 1787, no. 5, pp. 414–420, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Jiang, X. Fan, Y. Wang et al., “Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration,” Toxicological Sciences, vol. 143, no. 1, pp. 107–115, 2015. View at Publisher · View at Google Scholar
  47. Y.-S. Lee, J. Wan, B.-J. Kim, M.-A. Bae, and B. J. Song, “Ubiquitin-dependent degradation of p53 protein despite phosphorylation at its N terminus by acetaminophen,” Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 1, pp. 202–208, 2006. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Du, Y. Xie, M. R. McGill, and H. Jaeschke, “Pathophysiological significance of c-jun N-terminal kinase in acetaminophen hepatotoxicity,” Expert Opinion on Drug Metabolism and Toxicology, vol. 11, no. 11, pp. 1769–1779, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Saito, J. J. Lemasters, and H. Jaeschke, “C-Jun N-terminal kinase modulates oxidant stress and peroxynitrite formation independent of inducible nitric oxide synthase in acetaminophen hepatotoxicity,” Toxicology and Applied Pharmacology, vol. 246, no. 1-2, pp. 8–17, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. N. Hanawa, M. Shinohara, B. Saberi, W. A. Gaarde, D. Han, and N. Kaplowitz, “Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury,” The Journal of Biological Chemistry, vol. 283, no. 20, pp. 13565–13577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. E. A. Lock and J. Ishmael, “The nephrotoxicity and hepatotoxicity of 1,1,2,2-tetrafluoroethyl-L-cysteine in the rat,” Archives of Toxicology, vol. 72, no. 6, pp. 347–354, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Odum and T. Green, “The metabolism and nephrotoxicity of tetrafluoroethylene in the rat,” Toxicology and Applied Pharmacology, vol. 76, no. 2, pp. 306–318, 1984. View at Publisher · View at Google Scholar · View at Scopus
  53. A. J. L. Cooper and J. T. Pinto, “Aminotransferase, L-amino acid oxidase and β-lyase reactions involving L-cysteine S-conjugates found in allium extracts: relevance to biological activity?” Biochemical Pharmacology, vol. 69, no. 2, pp. 209–220, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. E. A. James, S. P. Gygi, M. L. Adams et al., “Mitochondrial aconitase modification, functional inhibition, and evidence for a supramolecular complex of the TCA cycle by the renal toxicant S-(1,1,2,2-tetrafluoroethyl)-L-cysteine,” Biochemistry, vol. 41, no. 21, pp. 6789–6797, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. H. K. Ho, Y. Jia, K. J. Coe et al., “Cytosolic heat shock proteins and heme oxygenase-1 are preferentially induced in response to specific and localized intramitochondrial damage by tetrafluoroethylcysteine,” Biochemical Pharmacology, vol. 72, no. 1, pp. 80–90, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. T. Bammler, R. P. Beyer, and S. Bhattacharya, “Standardizing global gene expression analysis between laboratories and across platforms,” Nature Methods, vol. 2, no. 5, pp. 351–356, 2005. View at Publisher · View at Google Scholar
  57. M. García Cortés, R. J. Andrade, M. I. Lucena et al., “Flutamide-induced hepatotoxicity: report of a case series,” Revista Espanola de Enfermedades Digestivas, vol. 93, no. 7, pp. 423–432, 2001. View at Google Scholar
  58. J.-L. Gomez, A. Dupont, L. Cusan et al., “Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients,” The American Journal of Medicine, vol. 92, no. 5, pp. 465–470, 1992. View at Publisher · View at Google Scholar · View at Scopus
  59. D. K. Wysowski and J. L. Fourcroy, “Flutamide hepatotoxicity,” The Journal of Urology, vol. 155, no. 1, pp. 209–212, 1996. View at Google Scholar · View at Scopus
  60. D. Fau, D. Eugene, A. Berson et al., “Toxicity of the antiandrogen flutamide in isolated rat hepatocytes,” Journal of Pharmacology and Experimental Therapeutics, vol. 269, no. 3, pp. 954–962, 1994. View at Google Scholar · View at Scopus
  61. K. J. Coe, Y. Jia, K. H. Han et al., “Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening,” Chemical Research in Toxicology, vol. 20, no. 9, pp. 1277–1290, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. S. D. Barrett, A. J. Bridges, D. T. Dudley et al., “The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 24, pp. 6501–6504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Hennig, M. T. Yip-Schneider, S. Wentz et al., “Targeting mitogen-activated protein Kinase Kinase with the inhibitor pd0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems,” Hepatology, vol. 51, no. 4, pp. 1218–1225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. P. D. Boasberg, C. H. Redfern, G. A. Daniels, D. Bodkin, C. R. Garrett, and A. D. Ricart, “Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer,” Cancer Chemotherapy and Pharmacology, vol. 68, no. 2, pp. 547–552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. W. Xia, R. J. Mullin, B. R. Keith et al., “Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways,” Oncogene, vol. 21, no. 41, pp. 6255–6263, 2002. View at Publisher · View at Google Scholar · View at Scopus
  66. W. C. Teng, J. W. Oh, L. S. New et al., “Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib,” Molecular Pharmacology, vol. 78, no. 4, pp. 693–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. L. Teo, M. Saetaew, S. Chanthawong et al., “Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence,” Breast Cancer Research and Treatment, vol. 133, no. 2, pp. 703–711, 2012. View at Publisher · View at Google Scholar · View at Scopus
  68. H. A. Friedel and A. Fitton, “Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states,” Drugs, vol. 45, no. 4, pp. 548–569, 1993. View at Publisher · View at Google Scholar · View at Scopus
  69. I. Szelenyi, “Flupirtine, a re-discovered drug, revisited,” Inflammation Research, vol. 62, no. 3, pp. 251–258, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. M. C. Michel, P. Radziszewski, C. Falconer, D. Marschall-Kehrel, and K. Blot, “Unexpected frequent hepatotoxicity of a prescription drug, flupirtine, marketed for about 30 years,” British Journal of Clinical Pharmacology, vol. 73, no. 5, pp. 821–825, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. K. Methling, P. Reszka, M. Lalk et al., “Investigation of the in vitro metabolism of the analgesic flupirtine,” Drug Metabolism and Disposition, vol. 37, no. 3, pp. 479–493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. C. J. Lemmerhirt, M. Rombach, A. Bodtke, P. J. Bednarski, and A. Link, “Oxidation potentials of N-modified derivatives of the analgesic flupirtine linked to potassium KV7 channel opening activity but not hepatocyte toxicity,” ChemMedChem, vol. 10, no. 2, pp. 368–379, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. C. Li, J. Ni, Z. Wang et al., “Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial,” Current Medical Research and Opinion, vol. 24, no. 12, pp. 3523–3530, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. M. J. Gomez-Lechon, M. T. Donato, J. V. Castell, and R. Jover, “Human hepatocytes as a tool for studying toxicity and drug metabolism,” Current Drug Metabolism, vol. 4, no. 4, pp. 292–312, 2003. View at Publisher · View at Google Scholar
  75. M. Vermeir, P. Annaert, R. N. V. S. Mamidi, D. Roymans, W. Meuldermans, and G. Mannens, “Cell-based models to study hepatic drug metabolism and enzyme induction in humans,” Expert Opinion on Drug Metabolism and Toxicology, vol. 1, no. 1, pp. 75–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Kang, D. Dalvie, E. Smith, S. Zhou, and A. Deese, “Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes,” Drug Metabolism and Disposition, vol. 35, no. 7, pp. 1081–1088, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. S. L. Arnaiz, S. Llesuy, J. C. Cutrín, and A. Boveris, “Oxidative stress by acute acetaminophen administration in mouse-liver,” Free Radical Biology and Medicine, vol. 19, no. 3, pp. 303–310, 1995. View at Publisher · View at Google Scholar · View at Scopus
  78. R. Kikkawa, M. Fujikawa, T. Yamamoto, Y. Hamada, H. Yamada, and I. Horii, “In vivo hepatotoxicity study of rats in comparison with in vitro hepatotoxicity screening system,” Journal of Toxicological Sciences, vol. 31, no. 1, pp. 23–34, 2006. View at Publisher · View at Google Scholar · View at Scopus
  79. Y. Xie, M. R. McGill, K. Dorko et al., “Mechanisms of acetaminophen-induced cell death in primary human hepatocytes,” Toxicology and Applied Pharmacology, vol. 279, no. 3, pp. 266–274, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. A. Costa, B. Sarmento, and V. Seabra, “An evaluation of the latest in vitro tools for drug metabolism studies,” Expert Opinion on Drug Metabolism and Toxicology, vol. 10, no. 1, pp. 103–119, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. H. K. Ho, C. C. White, C. Fernandez et al., “Nrf2 activation involves an oxidative-stress independent pathway in tetrafluoroethylcysteine-induced cytotoxicity,” Toxicological Sciences, vol. 86, no. 2, pp. 354–364, 2005. View at Publisher · View at Google Scholar · View at Scopus